Abstract
The word on the street has been out for some time — it's not true that the naloxone in the buprenorphine combination product (Suboxone, for example) prevents euphoria if the opioid, which is meant to be dissolved in the mouth, is ingested. More than 20 years ago, this was the premise when the federal government subsidized the development of the first buprenorphine‐naloxone product, paving the way for Reckitt Benckiser Pharmaceuticals — now Indivior — to make a fortune on its Suboxone product. There was yet another delay when the patent expired, but generic manufacturers couldn't break the code for blending the naloxone with the buprenorphine, furthering the fortunes of RBP/Indivior.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
